Assessing metastasis risk after pre-operative anti-angiogenic therapy.

EMBO Mol Med

The Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.

Published: December 2014

Anti-angiogenic drugs are approved for the treatment of several cancer types, generally in the inoperable locally advanced or metastatic setting and in combination with other anti‐cancer agents. Recent clinical studies also suggest that anti‐angiogenic drugs can be useful in the pre‐operative (neoadjuvant) setting, by facilitating the shrinkage of the primary tumour and its surgical resection. However, the effects of neoadjuvant anti‐angiogenic therapy on the ability of tumours to form distant metastases are unclear. In this issue of EMBO Molecular Medicine, Ebos et al (2014) present carefully performed pre-clinical studies in mice that analyse the effects of pre-operative anti-angiogenic therapy on tumour metastasis and survival.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287970PMC
http://dx.doi.org/10.15252/emmm.201404640DOI Listing

Publication Analysis

Top Keywords

pre-operative anti-angiogenic
8
anti-angiogenic therapy
8
assessing metastasis
4
metastasis risk
4
risk pre-operative
4
therapy anti-angiogenic
4
anti-angiogenic drugs
4
drugs approved
4
approved treatment
4
treatment cancer
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!